Harper N Price1. 1. aDivision of Dermatology, Phoenix Children's Hospital bUniversity of Arizona College of Medicine, Department of Child Health, Phoenix, AZ, USA.
Abstract
PURPOSE OF REVIEW: The article intends to review recent updates in the management of congenital melanocytic nevi (CMN) and the evolving genomic landscape that has begun to shed light on the nature of nevogenesis, malignant potential, and possible therapeutic targets for those with melanoma and neurologic involvement. RECENT FINDINGS: CMN are the result of postzygotic somatic mutations involving key proteins in the mitogen-activated protein kinase pathway, primarily NRAS and BRAF. Complications include a spectrum of neurologic findings and development of melanoma. Patients with extracutaneous involvement may be better termed as having 'CMN syndrome'. MRI findings in high risk patients with multiple CMN may best predict clinical outcome. SUMMARY: The management of patients with CMN is complex. Neurologic involvement and melanoma remain the two most devastating complications. New, genetically targeted therapies for patients with complications may be of value, and research for potential therapies is ongoing.
PURPOSE OF REVIEW: The article intends to review recent updates in the management of congenital melanocytic nevi (CMN) and the evolving genomic landscape that has begun to shed light on the nature of nevogenesis, malignant potential, and possible therapeutic targets for those with melanoma and neurologic involvement. RECENT FINDINGS: CMN are the result of postzygotic somatic mutations involving key proteins in the mitogen-activated protein kinase pathway, primarily NRAS and BRAF. Complications include a spectrum of neurologic findings and development of melanoma. Patients with extracutaneous involvement may be better termed as having 'CMN syndrome'. MRI findings in high risk patients with multiple CMN may best predict clinical outcome. SUMMARY: The management of patients with CMN is complex. Neurologic involvement and melanoma remain the two most devastating complications. New, genetically targeted therapies for patients with complications may be of value, and research for potential therapies is ongoing.
Authors: Martino Ruggieri; Agata Polizzi; Stefano Catanzaro; Manuela Lo Bianco; Andrea D Praticò; Concezio Di Rocco Journal: Childs Nerv Syst Date: 2020-10-13 Impact factor: 1.475
Authors: Yeon Sook Choi; Tal H Erlich; Max von Franque; Inbal Rachmin; Jessica L Flesher; Erik B Schiferle; Yi Zhang; Marcello Pereira da Silva; Alva Jiang; Allison S Dobry; Mack Su; Sharon Germana; Sebastian Lacher; Orly Freund; Ezra Feder; Jose L Cortez; Suyeon Ryu; Tamar Babila Propp; Yedidyah Leo Samuels; Labib R Zakka; Marjan Azin; Christin E Burd; Norman E Sharpless; X Shirley Liu; Clifford Meyer; William Gerald Austen; Branko Bojovic; Curtis L Cetrulo; Martin C Mihm; Dave S Hoon; Shadmehr Demehri; Elena B Hawryluk; David E Fisher Journal: Cell Date: 2022-05-12 Impact factor: 66.850
Authors: Katarzyna Wertheim-Tysarowska; Orest Szczygielski; Katarzyna Seliga; Andrzej Tysarowski; Jerzy Bal; Elżbieta Michalak; Agnieszka Magdalena Rygiel; Ewa Sawicka Journal: J Mother Child Date: 2021-10-11
Authors: Jasmine H Francis; Hans E Grossniklaus; Larissa A Habib; Brian Marr; David H Abramson; Klaus J Busam Journal: Invest Ophthalmol Vis Sci Date: 2018-01-01 Impact factor: 4.799
Authors: Luis A Pérez-Jurado; Víctor L Ruiz Pérez; Antonio Torrelo; Nancy B Spinner; Rudolf Happle; Leslie G Biesecker; Pablo Lapunzina; Víctor Martínez-Glez; Jair Tenorio; Julián Nevado; Gema Gordo; Lara Rodríguez-Laguna; Marta Feito; Raúl de Lucas Journal: Genet Med Date: 2020-07-14 Impact factor: 8.864